Document:

exh_101.htm

Exhibit 10.1

 

Fiscal Year 2012 Annual Cash Incentive Plan of Hutchinson Technology Incorporated

 

Our board of directors has adopted, upon the recommendation of its compensation committee, an annual cash incentive plan for fiscal year 2012 that covers executive officers and certain other key employees. The plan is designed to create an incentive for these officers and employees to achieve goals that our board of directors believes align with the long-term interests of our shareholders. The plan incorporates corporate financial measures and divisional strategic and financial measures.

 

Each executive officer is eligible for a target cash incentive opportunity equal to 40% to 100% of their respective base salary. Achievement of the minimum threshold for a particular goal is required before a participant is eligible to receive a payout for that goal. Actual performance between the minimum threshold and the goal results in a proportionate payout between 50% and 100% of the applicable portion of the target amount. Actual performance between the goal and the maximum threshold results in a proportionate payout between 100% and 200% of the applicable portion of the target amount. Actual performance above the maximum threshold results in a maximum payout of 200%.

 

A total of 50% of each executive officer’s cash incentive opportunity is based on achievement of two annual corporate financial goals. For fiscal year 2012, 30% of the cash incentive opportunity is based on the level of annual free cash flow achieved by our company during fiscal year 2012. The remaining 20% is based on our company’s earnings before taxes during the fiscal year. For a fiscal period, “free cash flow” equals the difference resulting from cash provided by operating activities less capital expenditures.

 

The remaining 50% of each executive officer’s cash incentive opportunity is based on achievement of annual division goals. For fiscal year 2012, the division goals for our Disk Drive Components Division are 45% based on the division’s market share, 45% based on cost per suspension assembly and 10% based on fiscal year 2012 revenue generated by leveraging the division’s precision component manufacturing capabilities. The division goals for our BioMeasurement Division for the same period are 30% based on annual revenue attributable to the division, 30% based on the division’s annual operating loss and 40% on annual sensor sales volume.

 

The minimum threshold for the earnings before taxes corporate financial goal must be achieved before a participant is eligible to receive any bonus payout for a divisional goal. Actual performance at the minimum threshold or more for both corporate financial goals must be achieved before a participant is eligible to receive greater than 100% of the target amount for any divisional goal.

 

For our chief executive officer, chief financial officer and vice president of human resources, 40% of their respective cash incentive opportunities are based on the division goals for our Disk Drive Components Division and 10% of their cash incentive opportunities are based on the division goals for our BioMeasurement Division. For our chief technology officer and the president of our Disk Drive Components Division, all of the remaining 50% of their respective cash incentive opportunities are based on the division goals for our Disk Drive Components Division.

 

The decision to make cash incentive payments is made annually by our board of directors upon the recommendation of its compensation committee. Payment amount are determined by the compensation committee and are made in cash in the first quarter of the following fiscal year. The compensation committee retains authority to adjust performance goals to exclude the impact of charges, gains or other factors that the compensation committee believes are not representative of the underlying financial or operational performance of our company.ex10-1.htm

Exhibit 10.1

SHARE TRANSFER CONTRACT

OF

SHAANXI WEINAN HUAREN PHARMACEUTICALS CO., LTD.

BY AND BETWEEN

SHAANXI AOXING PHARMACEUTICALS CO., LTD.

AND

SHAREHOLDERS OF SHAANXI WEINAN HUAREN PHARMACEUTICALS CO., LTD.

 

  

  

  

 

INDEX

 

	
CHAPATER I

	
DEFINITION AND INTERPRETATION

	
4

	
ARTICLE 1

	
DEFINITION

	
4

	
CHAPATER II

	
TRANSFERRED SHARES

	
5

	
ARTICLE 2

	
SHARE TRANSFER

	
5

	
ARTICLE 3

	
TRANSFER PRICE

	
5

	
ARTICLE 4

	
CONDITIONS FOR THE PAYMENT OF THE TRANSFER PRICE AND CLOSING

	
6

	
ARTICLE 5

	
PAYMENT

	
6

	
ARTICLE 6

	
TAX PAYABLE

	
7

	
ARTICLE 7

	
DRUG AND HEALTH PRODUCTS APPROVAL NUMBERS

	
7

	
CHAPATER III

	
REPRESENTATIONS AND WARRANTIES BY ALL PARTIES

	
7

	
ARTICLE 8

	
REPRESENTATIONS AND WARRANTIES BY ALL PARTIES

	
7

	
CHAPATER IV

	
DISCLOSURES, REPRESENTATIONS AND WARRANTIES BY THE TRANSFERORS

	
8

	
ARTICLE 9

	
DISCLOSURES, REPRESENTATIONS AND WARRANTIES BY THE TRANSFERORS

	
8

	
ARTICLE 10

	
GENERAL REPRESENTATIONS AND WARRANTIES BY TRANSFERORS

	
9

	
ARTICLE 11

	
OWNERSHIP

	
9

	
ARTICLE 12

	
SPECIAL REPRESENTATIONS AND WARRANTIES BY THE TRANSFERORS

	
10

	
CHAPATER V

	
DISCLOSURES, REPRESENTATIONS AND WARRANTIES OF TRANSFEREE

	
13

	
ARTICLE 13

	
DISCLOSURES, REPRESENTATIONS AND WARRANTIES OF THE TRANSFEREE

	
13

	
CHAPATER VI

	
EMPLOYEES

	
14

	
ARTICLE 14

	
EMPLOYEES

	
14

	
CHAPATER VII

	
CONFIDENTIALITY

	
14

	
ARTICLE 15

	
CONFIDENTIALITY

	
14

	
CHAPATER VIII

	
BREACH OF CONTRACT

	
15

	
ARTICLE 16

	
LIABILITIES FOR VIOLATION OF REPRESENTATIONS OR WARRANTIES

	
15

	
ARTICLE 17

	
LIABILITIES FOR BREACH OF CONTRACT

	
15

	
CHAPATER IX

	
FORCE MAJEURE

	
16

	
ARTICLE 18

	
FORCE MAJEURE

	
16

 

  

1

  

 

	
CHAPATER X

	
RESOLUTION OF DISPUTES

	
16

	
ARTICLE 19

	
ARBITRATION

	
16

	
ARTICLE 20

	
VALIDITY OF ARBITRAL AWARD

	
16

	
ARTICLE 21

	
CONTINUATION OF RIGHTS AND OBLIGATIONS

	
17

	
CHAPATER XI

	
APPLICABLE LAW

	
17

	
ARTICLE 22

	
APPLICABLE LAW

	
17

	
CHAPATER XII

	
MISCELLANEOUS

	
17

	
ARTICLE 23

	
NON-WAIVER

	
17

	
ARTICLE 24

	
TRANSFER

	
17

	
ARTICLE 25

	
AMENDMENT

	
17

	
ARTICLE 26

	
SEVERABILITY

	
18

	
ARTICLE 27

	
LANGUAGE

	
18

	
ARTICLE 28

	
EFFECTIVENESS OF TEXT AND APPENDIXES

	
18

	
ARTICLE 29

	
NOTIFICATION

	
18

	
ARTICLE 30

	
ENTIRE AGREEMENT

	
19

	 	 
	
APPENDIX I SHAREHOLDERS OF HUAREN

	21
	
APPENDIX II PRE-REQUISITE CONDITIONS

	22
	
APPENDIX III DRUG AND HEALTH PRODUCT APPROVAL NUMBERS

	23
	
APPENDIX IV DRUG APPROVAL NUMBERS FOR RE-REGISTRATION APPLICATION

	28

 

 

  

2

  

 

Share Transfer Contract

 

 

This Share Transfer Contract (hereinafter referred to as the “Contract”) is entered into by and between the following Parties in Xianyang, China on October 11, 2011:

	
(1)  

	
Party A: Shaanxi Aoxing Pharmaceuticals Co., Ltd. (hereinafter referred to as  “Transferee”),a company incorporated under PRC law;

	
(2)  

	
Party B: Shareholders of Shaanxi Weinan Huaren Pharmaceuticals Co., Ltd. as specified in Appendix I of this Contract (hereinafter referred to as “Transferors”).

Transferors and Transferee are hereinafter collectively as “Parties” and individually referred to as a “Party”.

WHEREAS,

	
(1)  

	
The Transferors hold 100% equity interests of Shaanxi Weinan Huaren Pharmaceuticals Co., Ltd. (hereinafter referred to as “Huaren”). The Transferors can exercise all of its full rights as the shareholders of Huaren;

	
(2)  

	
The Transferors agree to transfer all (100%) equity interests they collectively hold of Huaren to the Transferee in accordance with terms and conditions as stipulated hereunder (hereinafter referred to as “Transferred Shares”) ;

	
(3)  

	
The Transferee agrees to accept the transfer of all (100%) equity interests held by Transferors of Huaren in accordance with the terms and conditions as stipulated hereunder.

THEREFORE, in principle of equality and mutual benefits, through friendly negotiation, Parties hereto agree to reach, in accordance with Company Law of the People’s Republic of China, Contract Law of the People’s Republic of China and other applicable PRC laws and regulations, the following agreement.

  

3

  

Chapater I    Definition and Interpretation

	
Article 1  

	
Definition

Unless otherwise prescribed and stipulated, the following terms used in this Contract shall have the meanings set forth as follows:

“Huaren” refers to Shaanxi Weinan Huaren Pharmaceuticals Co., Ltd., a limited liability company incorporated under PRC law, with registered capital (paid-in capital) amounted to RMB 6,200,000, registration number of its legal and valid business license 610502100009599, registered at No.13 Weihua Avenue, Weinan City, Shaanxi Province.

“PRC” refers to, for purpose of the Contract, People’s Republic of China, excluding Hong Kong, Taiwan and Macau.

“Claim” means claims, actions, demands, proceedings judgments liabilities, damages amounts, costs and expenses (including all lawyers fees, legal costs and disbursements) whatsoever and howsoever arising.

“Signing Date” means the date on which this Contract is signed.

“Encumbrance” means any mortgage, assignment, lien, charge, pledge, title retention, right to acquire, security interest, option, pre-emptive right, and any other restriction or conditions whatsoever including:

(i)           any interest or right granted or reserved in or over or affecting the Transferred Shares for Transfer; or

(ii)           the interest or right created or otherwise arising in or over the Transferred Shares for Transfer under a fiduciary transfer, charge, lien, pledge, power of attorney or other form of encumbrance; or

(iii)           any security over the Transferred Shares for transfer for the payment of a debt or any other monetary obligation or the performance of any other obligation.

 “Material Adverse Change” refers to (1) Any investigation (would likely cause Huaren subject to an administrative punishment) or punishment on Huaren by governmental authorities; (2) Any suit, arbitration or any other judicial proceedings involving Huaren; (3) Any change would cause or reasonably may cause material adverse effect on the finance, business, properties, liabilities or operation results of Huaren or the prospect thereof.

“RMB” means the lawful currency of PRC.

  

4

  

 

“Third Party” means any natural person, legal person, other organization or entity, other than Parties hereto.

“Business Day” refers to any day on which all banks in Shaanxi are open for business.

Chapater II    Transferred Shares

	
Article 2  

	
Share Transfer

Pursuant to the terms stipulated in this Contract, the Transferors hereby agree to transfer to Transferee and Transferee agrees to accept from Transferors the Transferred Shares being one hundred percent (100%) of the equity interests of Huaren (namely, all capital contributions of Huaren) with all the rights and obligations attaching to the Transferred Shares for transfer including, but not limited to, general rights thereof, all the rights to receive dividends and to receive or subscribe for shares (if any) declared, paid or issued by Huaren (if any), and free of any Claim or Encumbrance.

	
Article 3  

	
Transfer Price

3.1 The Transferors and the Transferee after consultations have finally determined that the Transfer Price for the transfer of the Transferred Shares shall be RMB 61,000,000 (hereinafter referred to as “Transfer Price”);

3.2 Payment Term

3.2.1 The Parties hereby confirm that Transferee delivered RMB 30,000,000 as deposit to the Transferors on December 29, 2010 (hereinafter referred to as “Deposit”);

3.2.2 The Transferee shall pay RMB 15,000,000 to the Transferors within three (3) business days as of the Closing Date (as defined in Article 4.4). The balance, RMB 16,000,000, shall be paid after the following conditions are met: 1) the Transferors meet all pre-requisite conditions set out in Appendix II of this Contract (hereinafter referred to as “Pre-requisite Conditions”), 2) the Transferors pay the individual income tax regarding the Transferred Shares (hereinafter referred to as “Individual Income Tax”) in full according to PRC laws and regulations, and provide tax clearance certificates of Individual Income Tax issued by relevant tax authority within two(2) months as of the Signing Date,  3) the Transferors perform other duties required by the Transferee which are required to be fulfilled within two (2) months as of the Signing Date, and 4) Huaren is free of any material adverse change from the Signing Date to Final Payment Date (as defined in Article 5.1) (hereinafter collectively referred to as “Balance Payment Conditions”).

 

  

5

  

 

	
Article 4  

	
Conditions for the Payment of the Transfer Price and Closing

4.1 Under this Contract, the condition for the payment of RMB 15,000,000 is the satisfaction of Article 4.4. The conditions for the payment of the balance, RMB 16,000,000, are the satisfaction of the Balance Payment Conditions as stipulated in Article 3.2.2.

4.2 The Parties hereby confirm that the satisfaction of the Balance Payment Conditions shall be subject to the written confirmation by the Transferee. The Balance Payment Conditions shall not be deemed as having been satisfied until the Transferors obtain the written confirmation issued by the Transferee.

4.3 In the event that any of the conditions set out in Article 4.1 have not been satisfied or implemented, and Transferee has not indicated its waiver of the said conditions or any one of them, in writing, Transferee shall not be obliged to pay the Transfer Price to Transferors.

4.4 The Transferors and the Transferee hereby agree that the closing date shall be the date on which Huaren completes the share transfer registration with the Administration for Industry and Commerce where Huaren is registered (hereinafter referred to as “AIC”) within fifteen (15) business days as of the Signing Date, and the Transferee becomes the sole registered shareholder of Huaren (hereinafter referred to as “Closing Date”).

	
Article 5  

	
Payment

5.1 The Transferee shall pay RMB 15,000,000 to the bank account(s) designated by the Transferors within three (3) business days as of the Closing Date. The payment of the balance, RMB 16,000,000, shall be subject to Article 3.2.2. The payment date shall be the date when the Transferee pays RMB 15,000,000 to the Transferors (hereinafter referred to as “Payment Date”). The final payment date shall be the date when the balance RMB 16,000,000 is paid to the Transferors (hereinafter referred to as “Final Payment Date”).

5.2 The Transferors shall issue to Transferee the evidential document of the payment received within two (2) business days.

5.3 Within three (3) business days from the Closing Date, the Transferors shall hand over all materials to the Transferee or the representative designated by the Transferee, or the Transferors shall require relevant institutions or persons to transfer all materials of Huaren includes, but not limited to the official seal, financial seal, contract seal, account information, all accounting voucher, account book (including but not limited to personal seal and signature pre-submitted by Huaren to the bank changed to the personal seal and signature of the person designated by the Transferee), all official documents, licenses, permissions and client information relating to the business of Huaren, all contracts and agreements signed by Huaren, staff information, technical data and other relevant materials, and to take any measures to ensure the Transferee to control properties and business operation of Huaren.

 

  

6

  

 

	
Article 6  

	
Tax Payable

	
  

	
Any taxes or fees arising out of and payable pursuant to the fulfillment of the terms of this Contract by each of Transferors and Transferee shall be payable by the respective Party liable for the taxes or fees under the provisions of relevant PRC laws and regulations.

 

	
Article 7  

	
Drug and Health Products Approval Numbers

 

	
  

	
The Transferors shall transfer eighty-six (86) drug approval numbers and one (1) health products approval number set out in Appendix III to the Transferee (hereinafter referred to as “Approval Numbers”); the Transferors shall conduct re-registration application regarding the thirteen (13) drug approval numbers set out in Appendix IV (hereinafter referred to as “Re-registration Approval Numbers”) to competent authorities, and any fees arising from the application of Re-registration Approval Numbers shall be paid by the Transferors. Without the prior written consent of the Transferors, the Transferee cannot use the Re-registration Approval Numbers after the Closing Date.

Chapater III    Representations and Warranties by All Parties

 

	
Article 8

	
Representations and Warranties by All Parties

 

8.1 The Transferors and the Transferee confirm that this Contract shall be a document having legal binding effect on all Parties from the Signing Date.

8.2  At the time of signing this Contract, Transferors and the Transferee state that the documents and information provided to any other Party or their agencies (including without limitation to the lawyers, appraisers, financial consultants, etc.) prior to the Signing Date shall remain effective,and confirm that where there are discrepancies therein with the terms of this Contract, this Contract shall prevail.

 

  

7

  

 

8.3 The Transferors and the Transferee hereby agree that the contracts or documents pertaining to Transferred Shares entered into between all Parties prior to this Contract shall lapse automatically upon this Contract coming into effect.

8.4 Unless otherwise provided in this Contract, all rights and obligations enjoyed or assumed previously by the Transferors over Transferred Shares shall be entirely transferred to the Transferee after the Closing date.

8.5 All Parties to this Contract agree to strive jointly in coordinating the work pertaining to the transfer of the Transferred Shares, including but not limited to registration and filing of record, etc., and the expenses arising therefrom shall be borne by Huaren.

8.6 The board of directors of Huaren after the Closing Date (hereinafter referred to as “Board”) shall be composed of three directors who are all appointed by the Transferee. The Chief Financial Officer of Huaren shall also be appointed by the Transferee.

Chapater IV    Disclosures, Representations and Warranties by the Transferors

	
Article 9  

	
Disclosures, Representations and Warranties by the Transferors

The Transferors hereby jointly represent and warrant to the Transferee that:

9.1 All information and facts relating to Huaren that is in the possession of the Transferors or is known to any of the Transferors which will have a substantive and adverse effect on Transferors’ ability to fulfill any of its obligations in this Contract or when disclosed to Transferee shall have a substantive effect on the willingness of Transferee to sign and fulfill its obligations under this Contract, have been disclosed to Transferee and the information provided by Transferors to Transferee does not contain any representation that is untrue or misleading.

9.2 No lawsuits, arbitrations, or other legal or administrative proceedings or governmental investigations are on-going against the Transferors that will materially affect its ability to sign this Contract or fulfill its obligations under this Contract.

9.3 Regarding the documents and information provided by the Transferors to the Transferee and/or the Transferee’s agencies (including without limitation to the lawyers, appraisers, financial consultants, etc.) prior to the Signing Date, the Transferors hereby jointly undertake that:

	
9.3.1  

	
all copies made from original documents are true and complete;

	
9.3.2  

	
all original documents are authentic and complete;

	
9.3.3  

	
all documents supplied to the Transferee and/or the Transferee’s agencies as originals are authentic and complete;

	
9.3.4  

	
all signatures appearing on documents supplied to Transferee and/or Transferee’s agencies as originals or copies of originals are genuine; and

	
9.3.5  

	
Transferors have drawn to the attention of Transferee and/or Transferee’s agencies all matters that are material for Transferee to proceed with the transaction as contemplated in this Contract.

 

  

8

  

 

9.4 The Transferors agree to sign Non-Competition Agreements with Huaren and to ensure that the major management personnel and technical personnel of Huaren would sign Non-Competition Agreements with Huaren, which shall provide that, without the prior consent in writing by Huaren, such persons shall not be allowed to operate the business the same as or similar to the industry that Huaren and its clients or suppliers engage in, or other industries that are in competition with Huaren, or hold any equity interests of the entities mentioned hereinabove, unless the business or equity holding is via Huaren.

	
Article 10  

	
General Representations and Warranties by Transferors

The Transferors are PRC citizens with all civil abilities to enter into this Contract and fulfill all of their obligations stipulated herein. Signing this Contract and fulfilling all of their obligations stipulated herein by the Transferors shall not contravene or result in the violation of or constitute a failure to fulfill or an inability to fulfill any of the stipulations in any laws, regulations, stipulations, any authorization or approval from any government body or department or the stipulations of any contract or agreement that any of the Transferors is a Party to or is bound by.

	
Article 11  

	
Ownership

11.1 The Transferors are the legal owners of the Transferred Shares and have full authority and right to transfer the Transferred Shares to Transferee.

11.2 Transferors hereby jointly undertake and warrant up to and including the Payment Date that the Transferred Shares are not subject to any Claims or Encumbrances (including but not limited to any form of option, acquisition right, mortgage, pledge, guarantee, lien or any other form of Third Party rights).

11.3   No lawsuits, arbitrations, or other legal or administrative proceedings or governmental investigations are on-going against any of Transferors that will materially affect its ability to sign this Contract or fulfill its obligations under this Contract.

 

  

9

  

 

	
Article 12  

	
Special Representations and Warranties by the Transferors

The Transferors hereby specially represent and warrant to the Transferee that:

12.1 Huaren is a legal entity that has been duly incorporated in accordance with PRC laws and it is validly and legally in existence and also operating normally pursuant to PRC laws and regulations. The registered capital of Huaren has been fully paid and is free of any false capital contribution, overrated capital contribution and flight of capital contribution.

12.2 The Transferors hereby jointly warrant that Huaren legally and effectively owns the land use right, plants, machinery equipments and other properties currently occupied. The Transferors warrant that they will take any and all measures to guarantee Huaren legally obtains the right to use all land and obtain the ownership of all buildings with any right encumbrances, which shall not be subject to time and shall remain effective after the Closing Date. The Transferors shall assume the joint and several liabilities in case of any losses suffered by Huaren or the Transferee or any administrative penalties imposed by the governmental authorities due to any causes mentioned hereinabove after the share transfer under this Contact and indemnify the transferee for all losses arisen thereto.

 

12.3 There has not been and is not any investigation, prosecution, dispute, claim or other proceeding (whether current, pending or threatened) in respect of Huaren, nor Huaren has been punished or Transferors can foresee any punishment to be made by any administrative authorities of the PRC before the share transfer under this Contract, except for those disclosed to the Transferee prior to the Signing Date. The Transferors have fully disclosed all information of Huaren to the Transferee prior to the Signing Date. The Transferors hereby warrant that all tax, fees, charges, penalties and expenses payable to or required to pay to any PRC governmental authority have been fully paid. By the Signing Date, there has been no default in the payment of such tax, fees, charges, penalties and expenses, or any payable cost and/or expenses incurred by the correction of the default and/or inexpedient acts of Huaren required by any governmental authority. The Transferors shall assume the joint and several liabilities in case of any losses, damages or any penalties suffered by Huaren and/or the Transferee due to any investigation, prosecutions, disputes, claims or other proceedings prior to the share transfer under this Contract and shall fully indemnify the Transferee all losses arisen thereto.

12.4 The Transferors hereby warrant that Huaren has obtained all approvals, permissions, consents and fillings necessary to the production and business operation (including but not limited to Pharmaceutical Manufacturing Permit, Good Manufacturing Practices (GMP) Certificate, etc) which are all valid and legal, carried out businesses as stated in their business licenses, and executed contracts and documents with legally binding effects. The Transferors shall assume the joint and several liabilities in case of any losses, damages or any penalties suffered by Huaren or the Transferee due to any absence of the above-mentioned approvals, permissions, consents and fillings prior to the share transfer under this Contract and shall fully indemnify the Transferee all losses arisen thereto.

 

  

10

  

 

12.5 The Transferors hereby confirm and warrant that the production, operation and business of Huaren are in full compliance with the relevant PRC laws and regulations. The Transferors shall indemnify and hold the Transferee and Huaren harmless against and from any losses or damages caused by any administrative penalties thereto prior to the Signing Date.

12.6 The Transferors hereby confirm and warrant that the Transferors shall assume jointly and severally liabilities of Huaren to Huaren in order to hold the Transferee harmless for any undisclosed debts and the outstanding interest payable hereto.

12.7 The Transferors hereby irrevocably confirm and warrant that the Transferee shall have right to appoint the financial staffs to Huaren as of the Signing Date and all fiscal expenditure of Huaren shall be made upon the mutual consent in writing jointly by the financial staffs appointed by the Transferee and the financial staffs of the Transferors from the Signing Date to the Payment Date. The financial staffs of the Transferors will withdraw from Huaren and hand over all financial materials to financial staffs appointed by the Transferee for their sole control on the Payment Date.

12.8 The Transferors hereby confirm and warrant that they will ensure the normal operation and management of Huaren prior to the Payment Date and the operation, business and conditions of Huaren will be free of any material adverse change.

12.9 The Transferors hereby irrevocably represent and warrant that Huaren has not made any equity investment on any other companies or entities by the Payment Date. The Transferors shall assume the joint and several liabilities in case of any losses or damages suffered by Huaren or the Transferee in respect of the undisclosed equity investment (if any) and shall fully indemnify the Transferee all losses arisen thereto.

12.10 The Transferors hereby irrevocably represent and warrant that Huaren has not provided security (including but not limited to mortgage, pledge and guarantee) to any other companies, enterprises, entities or natural persons. The Transferors shall assume the joint and several liabilities in case of any losses or damages suffered by Huaren or/and the Transferee due to the undisclosed security and shall indemnify the Transferee all losses arisen thereto.

 

  

11

  

 

12.11 Prior to the Signing Date, Transferors have entirely disclosed all information regarding the debts assumed by Huaren. As of the Payment Date, such information remains complete, authentic, accurate and true.

12.12 The Transferors hereby confirm and warrant that Huaren has paid up all taxes required by PRC laws and regulations prior to the Payment Date. The Transferors shall assume the joint and several liabilities for any unpaid taxes of Huaren in order to hold harmless the Transferee against and from any loss and damages arisen thereto.

12.13 The Transferors hereby confirm and warrant that Huaren has obtained the necessary approvals for all of its production and construction projects (no matter whether the project is completed or under construction) from and registrations with relevant PRC governmental authorities, including, but not limited to, environmental impact assessment approvals and the completion acceptance approvals issued by the local environmental protection authority. The Transferors shall be jointly and severally liable to fully indemnify the Transferee in case of any administrative penalty suffered by Huaren arising from hereto due to aforesaid issues (disclosed or undisclosed) after the shares transfer of this Contract.

12.14 The Transferors hereby irrevocably confirm and warrant that the craftwork and technology Huaren adopts currently and the intellectual property owned by it prior to the Payment Date, including but not limited to trademarks, patents and know-how, are in full compliance with relevant PRC laws, regulations, standards or criterion, and free of any infringement of trademarks, patents and know-how of any Third Party. The Transferors shall be jointly and severally liable to fully indemnify the Transferee in case of any penalty, damages or losses suffered by Huaren arisen from such infringement.

12.15 The Transferors hereby irrevocably confirm and warrant that Huaren will obtain environmental impact assessment approvals and completion approvals issued by local environmental protection authority regarding the production and construction projects owned by Huaren within two (2) months from the Closing Date.

12.16 The Transferors hereby irrevocably confirm and warrant that Huaren legally holds Approval Numbers and prior to the Closing Date, Huaren has conducted related procedures of Approval Numbers whose original certificates are lost and required to be registered with relevant authorities and Re-registration Approval Numbers, and Huaren will obtain the certificates of such Approval Numbers and/or Re-registration Approval Numbers within two (2) months from the Signing Date. Any fees arising from the said procedures shall be borne by the Transferors.

 

  

12

  

 

12.17 The Transferors hereby irrevocably confirm and warrant that Huaren has signed labor contracts with all of its employees and paid all social insurances, including pension, unemployment insurance, occupational injury insurance, medical insurance maturity insurance and housing funds; the Transferors hereby further confirm and warrant that they shall be jointly and severally liable to fully indemnify the Transferee in case of any penalty, damages or losses suffered by Huaren and/or the Transferee in case Huaren fails to fulfill aforesaid obligations.

12.18 The Transferors hereby irrevocably confirm and warrant that all debts arising prior to the Closing Date shall be borne by the Transferors. The Transferors shall be jointly and severally liable to fully indemnify the Transferee in case of any penalty, damage or loss suffered by Huaren and/or the Transferee arisen from such debts.

12.19 The Transferee is entitled to require the Transferors to undertake the joint and several liabilities and indemnify and hold harmless the Transferee against and from any direct and indirect losses or damages in case of any infringement of any representations and warranties stated hereinabove by the Transferors, or in case that the Transferors fails to meet any or all Pre-requisite Conditions set out in Appendix II attached hereto.

Chapater V                      Disclosures, Representations and Warranties of Transferee

	
Article 13  

	
Disclosures, Representations and Warranties of the Transferee

The Transferee hereby represents and warrants to the Transferors that:

13.1 The Transferee is a legal entity that has been duly incorporated, and is validly and legally in existence and also operating normally in accordance with the PRC laws.

13.2 The execution and performance of this Contract by the Transferee will not contravene or result in the violation of or constitute a failure to fulfill or an inability to fulfill any of the stipulations of the Transferee’s articles of association or its internal rules, any laws, regulations, stipulations, or any authorizations or approvals from any government body or department or any contract or agreement that the Transferee is a Party to or is bound by.

13.3 No lawsuits, arbitrations, or other legal or administrative proceedings or governmental investigations are on-going against the Transferee that will materially affect its ability to sign this Contract or fulfill its obligations under this Contract.

  

13

  

Chapater VI    Employees

	
Article 14  

	
Employees

Upon the completion of the share transfer under this Contract, all current employees of Huaren shall continue to be employed. The terms and conditions of their employment including their remuneration for their employment will be implemented in accordance with the stipulations of the labor laws and regulations. Thereafter, Board will determine the staff numbers and working rules, etc., in consideration of business needs.

Chapater VII    Confidentiality

	
Article 15  

	
Confidentiality

	
15.1  

	
 All Parties agree, unless otherwise provided for in another relevant confidentiality agreement, that with regard to the confidential and exclusive information that have been disclosed to or may be disclosed to the other Parties by any Party to this Contract pertaining to their respective businesses, or financial situations and other confidential matters, all Parties to this Contract which have received the aforesaid confidential information (including written information and non-written information, hereinafter referred to as “Confidential Information”) shall:

15.1.1                Keep the aforesaid Confidential Information confidential;

	
  

	
15.1.2

	
Save for the disclosure of the Confidential Information by a Party to this Contract to its employees solely for the performance of their duties and responsibilities, neither Party to this Contract shall disclose the Confidential Information to any Third Party or any entity.

	
  

	
15.2 The provisions of the aforesaid Article 15.1 shall not apply to Confidential Information:

	
  

	
15.2.1

	
which was available to the receiving Party from the written record before the disclosing Party disclosed the information to the receiving Party and the written record can prove that the confidential information was already known to the receiving Party;

	
  

	
15.2.2

	
which has become public information by means not attributable to any breach by the receiving Party;

 

  

14

  

 

	
  

	
15.2.3

	
which was obtained, by the receiving Party from a Third Party not subject to any confidentiality obligation affecting the said Confidential Information.

15.3 As far as any natural person or legal entity which is a Party to this Contract is concerned, notwithstanding that it has ceased to be a Party to this Contract because of the transfer of its rights and obligations pursuant to the terms of this Contract, the stipulations set out in this Chapter VII shall remain binding on it.

Chapater VIII    Breach of Contract

	
Article 16  

	
Liabilities for Violation of Representations or Warranties

16.1 If any representation or warranty made by any Party to this Contract is found to be an error, or if any fact that has or is likely to have a major or substantial effect on the signing of this Contract by any Party has been omitted, or if any representation or warranty is found to be misleading or untrue in any material respect, the non-breaching Party shall be entitled to look to the Party (ies) in breach for full compensation for any loss, damage, cost or expense (including any attorneys’ fee and litigation and arbitration fee) arising from the erroneous, misleading or untrue representation or warranty of the Party (ies) in breach or arising from any other breach of any representation and warranty given by the Party (ies) in breach.

16.2 Each representation and warranty set out in this Contract is to be construed independently.

16.3 For the avoidance of doubt, the Transferors hereby unconditionally and irrevocably agree and confirm that they shall be jointly liable for any liability for any breach of representation or warranty.

	
Article 17  

	
Liabilities for Breach of Contract

17.1 In the event of a breach committed by any Party to this Contract, the said defaulting Party shall be liable to the other Party (ies) for any liabilities arising out of that defaulting Party’s breach of contract in accordance with the provisions of this Contract and the laws and regulations of PRC. In case of breach of Contract by all Parties hereto, a Party shall respectively assume liabilities for any loss or damage, or any other liabilities, arising out of its breach of Contract, against other Parties.

17.2 In the event that Huaren fails to complete the share transfer registration with AIC in accordance with Article 4.4, or the Transferors fail to meet any Pre-requisite Conditions set out in Appendix II or violates any representation, warranty or obligations under this Contract, without account of the intention or gross negligence of the Transferee, Transferors shall pay RMB 1,000,000 to the Transferee, in addition to the compensation for any direct or indirect loss arising therefrom.

 

  

15

  

 

Chapater IX    Force Majeure

	
Article 18  

	
Force Majeure

18.1 The Force Majeure shall include earthquake, typhoon, flood, fire, war, political unrest and such special incidents or events that are deemed to be Force Majeure occurrences under the provisions of the relevant laws and regulations of PRC.

18.2 In the event of the occurrence of a Force Majeure event, the obligations of the Party to

this Contract affected by this Force Majeure event shall cease during the period of the Force Majeure event and any term or period set out in this Contract and to which the affected Party is subject shall automatically be extended by a period equal to the term or period of the Force Majeure event, the period of extension shall be the same as the period of cessation of the obligations by reason of the Force Majeure event, and the said Party shall not be liable for any liabilities arising out of a breach of contract as provided for in this Contract for the duration of the Force Majeure.

18.3 The Party claiming the occurrence of a Force Majeure event shall promptly inform the

other Party (ies) in writing, and within seven (7) days thereafter, it shall provide sufficient evidence (issued by the notary organization) of the occurrence and the continuity of the Force Majeure event. It shall also do its best to eliminate the adverse effect of the Force Majeure event.

Chapater X    Resolution of Disputes

	
Article 19  

	
Arbitration

Any dispute arising out of this Contract between the Parties to this Contract shall firstly be resolved through friendly consultation. In case no settlement can be reached through consultation, either Party shall have the right to submit such dispute to China International Economic and Trade Arbitration Commission in Beijing for arbitration in accordance with then effective arbitration rules. The Place of arbitration is Beijing.

	
Article 20  

	
Validity of Arbitral Award

The arbitration award shall be final and shall be binding on all Parties to this Contract. All Parties to this Contract agree to be bound by the said award, and to act according to the terms of the said award.

 

  

16

  

 

	
Article 21  

	
Continuation of Rights and Obligations

After a dispute has arisen and during its arbitration process, other than the disputed matter, all Parties to this Contract shall continue to exercise their other respective rights stipulated in this Contract, and shall also continue to perform their other respective obligations stipulated in this Contract.

Chapater XI    Applicable Law

	
Article 22  

	
Applicable Law

The laws and regulations of the PRC shall govern and be binding on the establishment, validity, interpretation and execution of this Contract. All disputes arising out of this Contract shall be determined according to the laws of the PRC. In the event that the laws of the PRC do not make provision for a certain issue relating to this Contract, reference shall be made to general international business practice.

Chapater XII    Miscellaneous

	
Article 23  

	
Non-Waiver

The non-exercise or delay in the exercise of an entitlement stipulated in this Contract by any Party to this Contract shall not be regarded as a waiver of the said entitlement. Any single exercise or partial exercise of an entitlement shall not rule out any future re-exercise of the said entitlement.

	
Article 24  

	
Transfer

Unless otherwise described and prescribed in this Contract, neither Party to this Contract shall transfer or assign all or any part of this Contract or transfer or assign that Party’s entitlement or obligations as stipulated in this Contract.

	
Article 25  

	
Amendment

25.1 This Contract has been executed for the benefit of all Parties to this Contract and their respective lawful successor(s) and assignees, and shall have legal binding effect on them.

25.2 Any amendment to this Contract shall be made by the Parties in writing. The amendment duly executed by the Parties shall be deemed an integral part of this Contract and shall have the same legal effect as this Contract.

 

  

17

  

 

	
Article 26  

	
Severability

The invalidity of any term in this Contract shall not affect the validity of the other terms in this Contract.

	
Article 27  

	
Language

This Contract is written in Chinese and English. In case of any inconsistency, the Chinese version shall prevail.

	
Article 28  

	
Effectiveness of Text and Appendixes

28.1 The Contract shall be effective from the execution of Parties hereof (“Effective Date”). The Contract shall be written in twelve (12) original sets in Chinese, with the Transferors holding seven (7) original sets, the Transferee holding one (1) original set, the AIC holding one (1) original set, and the remaining shall be kept by Huaren and the Transferee.

28.2 The Appendix to this Contract shall form an integral part of this Contract, and shall have the same effect as this Contract

	
Article 29  

	
Notification

29.1 Unless otherwise specified and prescribed, any Party issuing any notification or written communication to the other Party (ies) according to the provisions of this Contract shall have them written in Chinese and shall send them as a letter by a courier service company, or by facsimile. Letters sent by a courier service company, will require a confirmation to be given seven (7) working days after handing over the notification or communication to the courier service company. Any notification or written communication sent in accordance with the stipulations of this Contract shall be deemed to be effective on the date of receipt.  If they are sent by facsimile, the date of receipt shall be deemed to be three (3) working days after transmission, subject to a facsimile confirmation report evidencing this.

 

  

18

  

 

29.2 All notices or communications shall be sent to the following addresses, unless and until any such address is changed by written notice to the other Party:

 

Address of the Transferee:No.588 Shiji Avenue, Xianyang City, Shaanxi Province

Postcode: 712046

Tel: (029) 33686638                                                      

Fax Number: (029) 33685386

To:Shuang Gong                                                      

 

Address of the Transferors:No.13 Weihua Avenue, Weinan City, Shaanxi Province

Postcode: 714000

Tel: (0913) 2090700

Fax Number: (0913) 2090702

To: Jian’guo Cao

 

	
Article 30  

	
Entire Agreement

This Contract constitutes the entire agreement of all Parties to this Contract pertaining to the transaction agreed upon in this Contract, and shall replace all the previous discussions, negotiations and agreements among all Parties to this Contract in respect of the transaction of this Contract.

    The remainder of this page is intentionally left blank)

 

  

19

  

 

IN WITNESS WHEREOF, the duly authorized representative of Party A and Party B have signed this Contract on the date first above written.

Party A:Shaanxi Aoxing Pharmaceuticals Co., Ltd.

(Seal)

Authorized Representative(Signature):                                                                                                          

Party B:Shareholders of Shaanxi Weinan Huaren Pharmaceuticals Co., Ltd.

Signature:

  

20

  

 

Appendix I Shareholders of Huaren

 

	
1.  

	
Jian’guo Cao,ID number 610402195504211815,holds 30% equity interests of Huaren;

	
2.  

	
Jun Wang,ID number 610125198605172212,holds 21% equity interests of Huaren;

	
3.  

	
Xiaoju Wang,ID number 610125197409186241,holds 10% equity interests of Huaren;

	
4.  

	
Meili Zhao,ID number 610404196705165525,holds 10% equity interests of Huaren;

	
5.  

	
Xibo Wu,ID number 610125198610022550,holds 10% equity interests of Huaren;

	
6.  

	
Ying Liu,ID number 610402198710060302,holds 9.5% equity interests of Huaren;

	
7.  

	
Biao Ning,ID number 610404198703254531,holds 9.5% equity interests of Huaren。

  

21

  

 

Appendix II Pre-requisite Conditions

 

Pre-requisite Conditions

Transferors hereby irrevocably guarantee to fulfill all following conditions precedent within the time limit on their own costs:

	
(A)  

	
The audited revenues of Huaren in the years of 2009 and 2010 shall be greater than RMB 21 million and 28 million respectively and the after tax net margin shall reach 15%. The said auditor refers to the auditor appointed by the Transferee.

	
(B)  

	
Transferors and Huaren complete the share transfer registration with the local AIC, and the shareholders of Huaren as registered with the AIC have been changed to the Transferee.

 

  

22

  

 

Appendix III Drug and Health Product Approval Numbers

Drug Approval Numbers

	
Serial Number

	
Drug Number

	
Approval Number

	
1

	
Piracetam Tablet

	
Guo Yao Zhun Zi H20054933

	
2

	
Bifendate Tablet

	
Guo Yao Zhun Zi H20054933

	
3

	
Paracetamol,Caffein ,Atificial Cow-bezoar and Chlorphenamine Maleate Capsule

	
Guo Yao Zhun Zi H20054935

	
4

	
Procaine Hydrochloride Injection

	
Guo Yao Zhun Zi H20054936

	
5

	
Nicorandil Tablet

	
Guo Yao Zhun Zi H20054937

	
6

	
Cystine Tablet

	
Guo Yao Zhun Zi H20054938

	
7

	
Anticoagulation Solution

	
Guo Yao Zhun Zi H20054939

	
8

	
Chlobamolie Hydrochloride Tablet

	
Guo Yao Zhun Zi H20054940

	
9

	
Berberine Hydrochloride and Trimethoprim Tablet

	
Guo Yao Zhun Zi H20054941

	
10

	
Compound Reserpine Tablet

	
Guo Yao Zhun Zi H20054942

	
11

	
Aspirin Enteric-coated Tablet

	
Guo Yao Zhun Zi H20054943

	
12

	
Aspirin Enteric-coated Tablet

	
Guo Yao Zhun Zi H20054944

	
13

	
Propafenone Hydrochloride Tablet

	
Guo Yao Zhun Zi H20054945

	
14

	
Erythromycin Estolate Granule

	
Guo Yao Zhun Zi H20054946

	
15

	
Erythromycin Estolate Granule

	
Guo Yao Zhun Zi H20054947

	
16

	
Erythromycin Estolate Tablet

	
Guo Yao Zhun Zi H20054948

 

  

23

  

 

	
17

	
Alginic Sodium Diester Tablet

	
Guo Yao Zhun Zi H20054949

	
18

	
Isosorbide Dinitrate Tablet

	
Guo Yao Zhun Zi H20054950

	
19

	
Ranitidine Hydrochloride Capsule

	
Guo Yao Zhun Zi H20054951

	
20

	
Propafenone Hydrochloride Tablet

	
Guo Yao Zhun Zi H20054952

	
21

	
Propafenone Hydrochloride Tablet

	
Guo Yao Zhun Zi H20054953

	
22

	
Tetracycline Hydrochloride Tablet

	
Guo Yao Zhun Zi H20054954

	
23

	
Tetracycline Hydrochloride Tablet

	
Guo Yao Zhun Zi H20054955

	
24

	
Ethambutol Hydrochloride Tablet

	
Guo Yao Zhun Zi H20054956

	
25

	
Pyritinol Hyorochloride Tabelet

	
Guo Yao Zhun Zi H20054957

	
26

	
Glucurolactone Tablet

	
Guo Yao Zhun Zi H20054958

	
27

	
Tabellae Acidi Oleanolici

	
Guo Yao Zhun Zi H20054959

	
28

	
Tabellae Acidi Oleanolici

	
Guo Yao Zhun Zi H20054960

	
29

	
Compound Aminopyrine Phenacetin Tablet

	
Guo Yao Zhun Zi H20054961

	
30

	
Vitamin C Tablet

	
Guo Yao Zhun Zi H20054962

	
31

	
Vitamin C Tablet

	
Guo Yao Zhun Zi H20054963

	
32

	
Vitamin C Tablet

	
Guo Yao Zhun Zi H20054964

	
33

	
Cimetidine Capsule

	
Guo Yao Zhun Zi H20054965

	
34

	
Cimetidine Tablet

	
Guo Yao Zhun Zi H20054966

	
35

	
Carbamazepine Tablet

	
Guo Yao Zhun Zi H20054967

	
36

	
Rifampicin Capsule

	
Guo Yao Zhun Zi H20054968

	
37

	
Rifampicin Capsule

	
Guo Yao Zhun Zi H20054969

 

  

24

  

 

	
38

	
Rifampicin Tablet

	
Guo Yao Zhun Zi H20054970

	
39

	
Sulfamethoxazole,Sulfadiazine and Trimethoprim Tablet

	
Guo Yao Zhun Zi H20054971

	
40

	
Benproperine Phosphate Tablet

	
Guo Yao Zhun Zi H20054972

	
41

	
Chloramphenicol Tablet

	
Guo Yao Zhun Zi H20054973

	
42

	
Aminophylline Tablet

	
Guo Yao Zhun Zi H20054974

	
43

	
Aminophylline Tablet

	
Guo Yao Zhun Zi H20054974

	
44

	
Metamizole Sodium Tablet

	
Guo Yao Zhun Zi H20054976

	
45

	
Metamizole Sodium Tablet

	
Guo Yao Zhun Zi H20054977

	
46

	
Paracetamol Tablet

	
Guo Yao Zhun Zi H20054978

	
47

	
Pipemidic acid Tablet

	
Guo Yao Zhun Zi H20054979

	
48

	
Pipemidic acid Tablet

	
Guo Yao Zhun Zi H20054980

	
49

	
Paracetamol Tablet

	
Guo Yao Zhun Zi H20054981

	
50

	
Paracetamol Tablet

	
Guo Yao Zhun Zi H20054982

	
51

	
Compound Aspirin Tablet

	
Guo Yao Zhun Zi H20054983

	
52

	
Compound Paracetamol Tablet

	
Guo Yao Zhun Zi H20054984

	
53

	
Erythromycin Enteric-coated Tablet

	
Guo Yao Zhun Zi H20054985

	
54

	
Erythromycin Enteric-coated Tablet

	
Guo Yao Zhun Zi H20054986

	
55

	
Sulfadiazine Tablet

	
Guo Yao Zhun Zi H20054987

	
56

	
Sulfamidine Tablet

	
Guo Yao Zhun Zi H20054988

	
57

	
Inosine Tablets

	
Guo Yao Zhun Zi H20054989

	
58

	
Inosine Tablet

	
Guo Yao Zhun Zi H20054993

 

  

25

  

 

	
59

	
Metronidazole Tablet

	
Guo Yao Zhun Zi H20054994

	
60

	
Trimethoprim Tablet

	
Guo Yao Zhun Zi H20054997

	
61

	
Fosfomycin Calcium Capsule

	
Guo Yao Zhun Zi H20054998

	
62

	
Tabellae Antipyrini Et Caffeini Citratis

	
Guo Yao Zhun Zi H20054999

	
63

	
Tolperisone Hydrochloride Tablet

	
Guo Yao Zhun Zi H20055000

	
64

	
Tolperisone Hydrochloride Tablet

	
Guo Yao Zhun Zi H20055001

	
65

	
Tolperisone Hydrochloride Tablet

	
Guo Yao Zhun Zi H20055002

	
66

	
Erythronycin Stearate Tablet

	
Guo Yao Zhun Zi H20055003

	
67

	
Erythronycin Stearate Tablet

	
Guo Yao Zhun Zi H20055004

	
68

	
Erythronycin Stearate Tablet

	
Guo Yao Zhun Zi H20055005

	
69

	
Aspirin Tablet

	
Guo Yao Zhun Zi H20055006

	
70

	
Aspirin Tablet

	
Guo Yao Zhun Zi H20055007

	
71

	
Aspirin Enteric-coated Tablet

	
Guo Yao Zhun Zi H20055008

	
72

	
Tetracycline Hydrochloride Tablet

	
Guo Yao Zhun Zi H20055009

	
73

	
Tetracycline Hydrochloride Tablet

	
Guo Yao Zhun Zi H20055010

	
74

	
Huangyangning Tablets

	
Guo Yao Zhun Zi Z61020805

	
75

	
Longdan Xiegan Pill

	
Guo Yao Zhun Zi Z61021149

	
76

	
Norfloxacin Capsule

	
Guo Yao Zhun Zi H61021705

	
77

	
Berberine Hydrochloride Tablet

	
Guo Yao Zhun Zi H20055000

	
78

	
Fufang Danshen Tablet

	
Guo Yao Zhun Zi Z61021148

	
79

	
Vitamin C Yinqiao Tablet

	
Guo Yao Zhun Zi Z61021150

 

  

26

  

 

	
80

	
Compound Sulfamethoxazole Tablet

	
Guo Yao Zhun Zi H61021609

	
81

	
Huanglian Shangqing Pill

	
Guo Yao Zhun Zi Z61020804

	
82

	
Muxiang Shunqi Pill

	
Guo Yao Zhun Zi Z61020806

	
83

	
Wenweishu Capsule

	
Guo Yao Zhun Zi Z20053280

	
84

	
Jiakangling Capsule

	
Guo Yao Zhun Zi Z20050163

	
85

	
Zhitong Tougu Plaster

	
Guo Yao Zhun Zi Z20043369

	
86

	
Qianlietong Capsule

	
Guo Yao Zhun Zi Z20050128

Health Products Approval Number

	
Serial Number

	
Health Product Name

	
Approval Name

	
1

	
Huaren Changweitong Capsule

	
Guo Shi Jian Zi G20040342

  

27

  

 

Appendix IV Drug Approval Numbers for Re-registration Application

 

	
Serial Number

	
Drug Name

	
Approval Number

	
1

	
Jin’gang Tablet

	
Guo Yao Zhun Zi Z20053915

	
2

	
Danxiang Rhinitis Tablet

	
Guo Yao Zhun Zi Z20063984

	
3

	
Azithromycin Dispersible Tablet

	
Guo Yao Zhun Zi H20063547

	
4

	
Fuke Zhidai Tablet

	
Guo Yao Zhun Zi Z20063475

	
5

	
Chuzhangze Haifu Tablet

	
Guo Yao Zhun Zi Z20063355

	
6

	
Erlong Zuoci Pill

	
Guo Yao Zhun Zi Z20063331

	
7

	
Erlong Tongqiao Pill

	
Guo Yao Zhun Zi Z20064318

	
8

	
Vitligo Capsule

	
Guo Yao Zhun Zi Z20044243

	
9

	
Sifangwei Capsule

	
Guo Yao Zhun Zi Z20063171

	
10

	
Yanlixiao Capsule

	
Guo Yao Zhun Zi Z20063139

	
11

	
Liganlong Capsule

	
Guo Yao Zhun Zi Z20063532

	
12

	
Nuan’gong Yunzi Capsule

	
Guo Yao Zhun Zi Z20083379

	
13

	
Peikun Capsule

	
Guo Yao Zhun Zi Z20093710

  

28

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00194-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00194-of-00352.parquet"}]]